Top

Published in:

12-12-2023 | ASO Author Reflections

ASO Author Reflections: Financial Toxicity and CRS-HIPEC—Is a Pound of Debt Worth an Ounce of Cure?

Authors: Yusuf Ciftci, BS, Shannon N. Radomski, MD, Fabian M. Johnston, MD, MHS, Jonathan B. Greer, MD

Published in: Annals of Surgical Oncology | Issue 4/2024

Excerpt

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a resource-intensive procedure that is associated with long operative times, lengthy hospitalizations, and considerable morbidity. As a result, CRS-HIPEC is expensive, with prior studies estimating the total cost to be in the range of $38,369–$49,248.^1,2 Although the financial impact of surgery on patients, termed financial toxicity, has been studied in the context of various oncologic procedures, there have been no studies investigating financial toxicity among patients undergoing CRS-HIPEC.³ We examined the incidence and risk factors for financial toxicity in this patient population. …

Squires MH 3rd, Staley CA, Knechtle W, Winer JH, Russell MC, Perez S, et al. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications. Ann Surg Oncol. 2015;22(5):1739–45. https://doi.org/10.1245/s10434-014-4025-7.CrossRefPubMed

Naffouje SA, O’Donoghue C, Salti GI. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: a cost-utility analysis of a hospital’s initial experience and reflections on the health care system. J Surg Oncol. 2016;113:544–7.CrossRefPubMed

Farooq A, Merath K, Hyer JM, Paredes AZ, Tsilimigras DI, Sahara K, et al. Financial toxicity risk among adult patients undergoing cancer surgery in the United States: an analysis of the National Inpatient Sample. J Surg Oncol. 2019;120(3):397–406. https://doi.org/10.1002/jso.25605.CrossRefPubMed

Ciftci Y, Radomski SN, Johnston FM, Greer JB. Predictors of financial toxicity risk among patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-14577-y.CrossRefPubMed

Title: ASO Author Reflections: Financial Toxicity and CRS-HIPEC—Is a Pound of Debt Worth an Ounce of Cure?
Authors: Yusuf Ciftci, BS
Shannon N. Radomski, MD
Fabian M. Johnston, MD, MHS
Jonathan B. Greer, MD
Publication date: 12-12-2023
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 4/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-14768-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ASO Author Reflections: Financial Toxicity and CRS-HIPEC—Is a Pound of Debt Worth an Ounce of Cure?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2024

ASO Author Reflections: A Novel Technique of Transaxillary Reverse-Sequence Endoscopic Nipple-Sparing Mastectomy and Direct-to-Implant Prepectoral Breast Reconstruction

ASO Visual Abstract: Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence

Letter to the Editor of Annals of Surgical Oncology Concerning “Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA”

Comparison Results of Three-Port Robot-Assisted and Uniportal Video-Assisted Lobectomy for Functional Recovery Index in the Treatment of Early Stage Non-small Cell Lung Cancer: A Propensity Score-Matched Analysis

Educating Cancer-Associated Fibroblasts (CAFs): Are They the Student or the Teacher?

ASO Visual Abstract: Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors